胆管病变及其相关肝脏疾病的研究现状

徐加敏; 唐映梅

doi:10.3969/j.issn.1001-5256.2019.04.051

胆管病变及其相关肝脏疾病的研究现状

DOI: 10.3969/j.issn.1001-5256.2019.04.051

昆明医科大学第二附属医院消化内科

基金项目:

国家自然科学基金(81660102)；昆明医科大学研究生创新基金(2018S124)；云南省自然科学基金(201701UH00618)；云南省卫生科技计划项目(2017NS280)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1089
- HTML全文浏览量: 12
- PDF下载量: 305
- 被引次数: 0
出版历程
- 出版日期: 2019-04-20

Current status of research on bile duct lesions and related liver diseases

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要: 胆管是肝内胆汁转运的通道,衬附其内的上皮细胞在形态和功能上具有异质性,是多种胆管病变的靶细胞。胆管上皮细胞除参与胆汁代谢和分泌外,还与组织损伤及修复相关。胆管上皮细胞具有免疫屏障功能,能分泌促炎因子和趋化因子。在内外源因子刺激下,胆管上皮细胞呈现出反应性并启动宿主免疫反应。总结了胆管病变及相关肝脏疾病的研究现状。
- 胆管疾病 /
- 肝疾病 /
- 综述
Abstract: The bile duct is the channel for bile transport in the liver, and the lining epithelial cells in the bile duct have functional and morphological heterogeneity and are the target of various bile duct diseases. In addition to bile metabolism and secretion, biliary epithelial cells are also involved in tissue damage and repair. Biliary epithelial cells have an immune barrier function and can secrete different proinflammatory factors and chemokines. Under the stimulation of endogenous and exogenous factors, biliary epithelial cells present immune reactivity and initiate immune response in the host. This article reviews the current status of research on bile duct lesions and related liver diseases.
- bile duct diseases /
- liver diseases /
- review

HTML全文

参考文献(48)

[1]CHEUNG AC, LORENZO PISARELLO MJ, LARUSSO NF. Pathobiology of biliary epithelia[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1220-1231.

[2]ALPINI G, MCGILL JM, LARUSSO NF. The pathobiology of biliary epithelia[J]. Hepatology, 2002, 35 (5) :1256-1268.

[3]STRAZZABOSCO M, FABRIS L. Functional anatomy of normal bile ducts[J]. Anat Rec (Hoboken) , 2008, 291 (6) :653-660.

[4]LUDWIG J. New concepts in biliary cirrhosis[J]. Semin Liver Dis, 1987, 7 (4) :293-301.

[5]HAN Y, GLASER S, MENG F, et al. Recent advances in the morphological and functional heterogeneity of the biliary epithelium[J]. Exp Biol Med (Maywood) , 2013, 238 (5) :549-565.

[6]GLASER SS, GAUDIO E, RAO A, et al. Morphological and functional heterogeneity of the mouse intrahepatic biliary epithelium[J]. Lab Invest, 2009, 89 (4) :456-469.

[7]PRIESTER S, WISE C, GLASER SS. Involvement of cholangiocyte proliferation in biliary fibrosis[J]. World J Gastrointest Pathophysiol, 2010, 1 (2) :30-37.

[8]MANCINELLI R, ONORI P, DEMORROW S, et al. Role of sex hormones in the modulation of cholangiocyte function[J].World J Gastrointest Pathophysiol, 2010, 1 (2) :50-62.

[9]YOO KS, LIM WT, CHOI HS. Biology of cholangiocytes:From bench to bedside[J]. Gut Liver, 2016, 10 (5) :687-698.

[10]SYAL G, FAUSTHER M, DRANOFF JA. Advances in cholangiocyte immunobiology[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303 (10) :g1077-g1086.

[11]SCHRUMPF E, TAN C, KARLSEN TH, et al. The biliary epithelium presents antigens to and activates natural killer T cells[J]. Hepatology, 2015, 62 (4) :1249-1259.

[12]SASAKI M, SATO Y, NAKANUMA Y. An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis[J]. Lab Invest, 2018, 98 (6) :745-754.

[13]LAZARIDIS KN, LARUSSO NF. The cholangiopathies[J].Mayo Clin Proc, 2015, 90 (6) :791-800.

[14]PINTO C, GIORDANO DM, MARONI L, et al. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1270-1278.

[15]O’HARA SP, TABIBIAN JH, SPLINTER PL, et al. The dynamic biliary epithelia:Molecules, pathways, and disease[J]. J Hepatol, 2013, 58 (3) :575-582.

[16]MARONI L, HAIBO B, RAY D, et al. Functional and structural features of cholangiocytes in health and disease[J]. Cell Mol Gastroenterol Hepatol, 2015, 1 (4) :368-380.

[17]ZHANG H, LEUNG P SC, GERSHWIN ME, et al. How the biliary tree maintains immune tolerance?[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt B) :1367-1373.

[18]KAWATA K, KOBAYASHI Y, GERSHWIN ME, et al. The immunophysiology and apoptosis of biliary epithelial cells:Primary biliary cirrhosis and primary sclerosing cholangitis[J]. Clin Rev Allergy Immunol, 2012, 43 (3) :230-241.

[19]TSUNEYAMA K, BABA H, MORIMOTO Y, et al. Primary biliary cholangitis:Its pathological characteristics and immunopathological mechanisms[J]. J Med Invest, 2017, 64 (1. 2) :7-13.

[20]NAKANUMA Y, SASAKI M, HARADA K. Autophagy and senescence in fibrosing cholangiopathies[J]. J Hepatol, 2015, 62 (4) :934-945.

[21]TABIBIAN JH, O'HARA SP, SPLINTER PL, et al. Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis[J]. Hepatology, 2014, 59 (6) :2263-2275.

[22]SHIMODA S, TANAKA A. It is time to change primary biliary cirrhosis (PBC) :New nomenclature from “cirrhosis” to“cholangitis”, and upcoming treatment based on unveiling pathology[J]. Hepatol Res, 2016, 46 (5) :407-415.

[23]LUDWIG J. The pathology of primary biliary cirrhosis and autoimmune cholangitis[J]. Baillieres Best Pract Res Clin Gastroenterol, 2000, 14 (4) :601-613.

[24]TSUNEYAMA K, HARADA K, YASOSHIMA M, et al. Expression of co-stimulatory factor B7-2 on the intrahepatic bile ducts in primary biliary cirrhosis and primary sclerosing cholangitis:An immunohistochemical study[J]. J Pathol, 1998, 186 (2) :126-130.

[25]TSUNEYAMA K, van de WATER J, LEUNG PS, et al. Abnormal expression of the E2 component of the pyruvate dehydrogenase complex on the luminal surface of biliary epithelium occurs before major histocompatibility complex class II and BB1/B7 expression[J]. Hepatology, 1995, 21 (4) :1031-1037.

[26]HARADA K, ISSE K, NAKANUMA Y. Interferon gamma accelerates NF-kappaB activation of biliary epithelial cells induced by Toll-like receptor and ligand interaction[J]. J Clin Pathol, 2006, 59 (2) :184-190.

[27]BOONSTRA K, BEUERS U, PONSIOEN C Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:A systematic review[J]. J Clin Pathol, 2012, 56 (5) :1181-1188.

[28]TAM PKH, YIU RS, LENDAHL U, et al. Cholangiopathies-towards a molecular understanding[J]. EBio Medicine, 2018, 35 (3) :381-393.

[29]NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375 (7) :631-643.

[30]CORPECHOT C, CHAZOUILLERES O, ROUSSEAU A, et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 378 (23) :2171-2181.

[31]CORPECHOT C, CHAZOUILLERES O, ROUSSEAU A. Bezafibrate in primary biliary cholangitis[J]. N Engl J Med, 2018, 379 (10) :985.

[32]DYSON JK, BEUERS U, JONES DEJ, et al. Primary sclerosing cholangitis[J]. Lancet, 2018, 391 (10139) :2547-2559.

[33]GIORDANO DM, PINTO C, MARONI L, et al. Inflammation and the gut-liver axis in the pathophysiology of cholangiopathies[J]. Int J Mol Sci, 2018, 19 (10) . pii:E3003.

[34]TABIBIAN JH, ALI AH, LINDOR KD. Primary sclerosing cholangitis, Part 2:Cancer risk, prevention, and surveillance[J]. Gastroenterol Hepatol (N Y) , 2018, 14 (7) :427-432.

[35]TAM PKH, CHUNG PHY, St PETER SD, et al. Advances in paediatric gastroenterology[J]. Lancet, 2017, 390 (10099) :1072-1082.

[36]KILGORE A, MACK CL. Update on investigations pertaining to the pathogenesis of biliary atresia[J]. Pediatr Surg Int, 2017, 33 (12) :1233-1241.

[37]MURAJI T, OHTANI H, IEIRI S. Unique manifestations of biliary atresia provide new immunological insight into its etiopathogenesis[J]. Pediatr Surg Int, 2017, 33 (12) :1249-1253.

[38]HARADA K. Sclerosing and obstructive cholangiopathy in biliary atresia:Mechanisms and association with biliary innate immunity[J]. Pediatr Surg Int, 2017, 33 (12) :1243-1248.

[39]ERICKSON N, MOHANTY SK, SHIVAKUMAR P, et al. Temporal-spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia[J]. Hepatology, 2008, 47 (5) :1567-1577.

[40]SASAKI H, NIO M, IWAMI D, et al. E-cadherin, alpha-catenin and beta-catenin in biliary atresia:Correlation with apoptosis and cell cycle[J]. Pathol Int, 2001, 51 (12) :923-932.

[41]PETERSEN C, DAVENPORT M. Aetiology of biliary atresia:What is actually known?[J]. Orphanet J Rare Dis, 2013, 8:128.

[42]LI HB, FU HY, LU TY, et al. Review of important progress in liver transplantation in 2017[J]. Ogran Transplantation, 2018, 9 (1) :41-50, 82. (in Chinese) 李海波, 符洪源, 陆桐宇, 等.肝移植领域2017年度重要进展盘点[J].器官移植, 2018, 9 (1) :41-50, 82.

[43]KARIMIAN N, WESTERKAMP AC, PORTE RJ. Biliary complications after orthotopic liver transplantation[J]. Curr Opin Organ Transplant, 2014, 19 (3) :209-216.

[44]RODRIGUEZ-PERALVAREZ M, de LUCA L, CRESPO G, et al. An objective definition for clinical suspicion of T-cell-mediated rejection after liver transplantation[J]. Clin Transplant, 2017, 31 (7) .

[45]BRAIN JG, ROBERTSON H, THOMPSON E, et al. Biliary epithelial senescence and plasticity in acute cellular rejection[J].Am J Transplant, 2013, 13 (7) :1688-1702.

[46]TANG Y, CHU H, CAO G, et al. S-Adenosylmethionine attenuates bile duct early warm ischemia reperfusion injury after rat liver transplantation[J]. Mol Immunol, 2018, 95:83-90.

[47]MAIONE F, GILBO N, LAZZARO S, et al. Porcine isolated liver perfusion for the study of ischemia reperfusion injury:A systematic review[J]. Transplantation, 2018, 102 (7) :1039-1049.

[48]WU YQ, HU ZM, HE K, et al. Prevention of biliary complications in organ donation liver transplantation after the death of a citizen[J]. Ogran Transplantation, 2017, 8 (4) :299-303. (in Chinese) 武玉强, 胡泽民, 何坤, 等.公民逝世后器官捐献供肝移植胆道并发症的预防经验[J].器官移植, 2017, 8 (4) :299-303.

施引文献

资源附件(0)

访问统计